Display options
Cite
Hicks J, Klumpp-Thomas C, Kalish H, et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv. 2020;doi: 10.1101/2020.06.22.20137695.
Hicks, J., Klumpp-Thomas, C., Kalish, H., Shunmugavel, A., Mehalko, J., Denson, J. P., Snead, K., Drew, M., Corbett, K., Graham, B., Hall, M. D., Memoli, M. J., Esposito, D., & Sadtler, K. (2020). Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.06.22.20137695
Hicks, Jennifer, et al. "Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.06.22.20137695
Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead K, Drew M, Corbett K, Graham B, Hall MD, Memoli MJ, Esposito D, Sadtler K. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv. 2020 Jun 23; doi: 10.1101/2020.06.22.20137695. PMID: 32596697; PMCID: PMC7315998.
Copy Download .nbib Format: NLM
Share it on

medRxiv. 2020 Jun 23; doi: 10.1101/2020.06.22.20137695.

Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses.

medRxiv : the preprint server for health sciences

Jennifer Hicks, Carleen Klumpp-Thomas, Heather Kalish, Anandakumar Shunmugavel, Jennifer Mehalko, John-Paul Denson, Kelly Snead, Matthew Drew, Kizzmekia Corbett, Barney Graham, Matthew D Hall, Matthew J Memoli, Dominic Esposito, Kaitlyn Sadtler

Affiliations

  1. Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda MD 20894.
  2. Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda MD 20892.
  3. National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD, 20850.
  4. Protein Expression Laboratory, NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  5. Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892.
  6. LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20894.

PMID: 32596697 PMCID: PMC7315998 DOI: 10.1101/2020.06.22.20137695

Abstract

In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other Betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.

References

  1. Curr Protoc Microbiol. 2020 Jun;57(1):e100 - PubMed
  2. Science. 2020 May 8;368(6491):630-633 - PubMed
  3. Sci Adv. 2019 Apr 10;5(4):eaav4580 - PubMed
  4. Clin Vaccine Immunol. 2010 Dec;17(12):1875-80 - PubMed
  5. Lancet. 2020 Apr 4;395(10230):1101-1102 - PubMed
  6. J Clin Virol. 2012 Feb;53(2):135-9 - PubMed
  7. J Clin Microbiol. 2020 May 26;58(6): - PubMed
  8. J Virol. 2003 Aug;77(16):8801-11 - PubMed
  9. Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6 - PubMed
  10. Science. 2020 Mar 13;367(6483):1260-1263 - PubMed
  11. Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357 - PubMed
  12. Protein Expr Purif. 2020 Jun 4;174:105686 - PubMed
  13. Annu Rev Virol. 2016 Sep 29;3(1):237-261 - PubMed
  14. Nat Rev Microbiol. 2009 Mar;7(3):226-36 - PubMed
  15. Nat Med. 2020 Jun;26(6):845-848 - PubMed
  16. Adv Virus Res. 2018;100:163-188 - PubMed
  17. J Clin Microbiol. 2010 Aug;48(8):2940-7 - PubMed

Publication Types

Grant support